Compare Fabrinet (FN) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Tenet Healthcare Corporation — how do they compare? Fabrinet trades at $465.53 (market cap $17.44B), while Tenet Healthcare Corporation trades at $198.94 (market cap $16.57B). The key difference: Fabrinet and Tenet Healthcare Corporation are close in size by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals.
| FN | THC | |
|---|---|---|
Market Cap | $17.44B | $16.57B |
Sector | Technology | Health |
52-Week High | $746.47 | $244.80 |
52-Week Low | $277.04 | $148.38 |
Enterprise Value | $16.50B | $26.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.
FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.
Tenet Healthcare (THC) trades at $199.10, up 8.39% over the past day, with strong fundamental metrics including a P/E of 10 and net income margin of 7.79%. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show a bearish trend with support at $187 and resistance at $197, while analyst sentiment remains overwhelmingly positive with 26 buy ratings and a consensus price target of $235.88.
The outlook for THC is favorable due to robust earnings performance and attractive valuation, though near-term price volatility and competitive pressures in healthcare pose risks. Revenue growth is projected to increase from $21.3B in 2025 to $21.9B in 2026, supporting further upside if execution continues. Investors should monitor Q2 2026 earnings due July 24, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
